LeslieAAndritsosMD

Hematology • Albuquerque, NM

Hematologic Oncology

Professor of Internal Medicine, Division of Hematology/Oncology, University of New Mexico Comprehensive Cancer Center

Join to view full profile

Dr. Andritsos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Andritsos' full profile

Already have an account?

Office
1 University of New Mexico
Albuquerque, NM 87131
Phone+1 505-272-4946

Fax+1 505-925-0100

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2001 - 2005
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1999 - 2001
University of Texas Medical Branch School of MedicineClass of 1999

Certifications & Licensure

NM State Medical License 2018 - 2025
MO State Medical License 2003 - 2023
OH State Medical License 2006 - 2019
AZ State Medical License 2005 - 2007
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Alpha Omega Alpha
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2006 Sep 01
Terminated
Phase 1
Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. Start of enrollment: 2007 Apr 01
Completed
Phase 1
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Completed
Phase 1
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers Start of enrollment: 2010 Nov 24
Completed
Phase 1
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2012 Feb 09
Completed
Phase 1, Phase 2
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Start of enrollment: 2014 Jan 17
Active, not recruiting
Phase 2
Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer Start of enrollment: 2016 Jan 27
Recruiting
Join now to see all

Publications & Presentations

PubMed

Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study.
Leslie A Andritsos, Ali McBride, Derek Tang, Victoria Barghout, Enrico Zanardo
Leukemia Research. 2024-11-17
Incidence, description, and timing of serious and opportunistic infections in patients with hairy cell leukemia.
Nilesh Kapoor, Qiuhong Zhao, Andrew Stiff, Seema A Bhat, Mirela I Anghelina
Ejhaem. 2024-10-01
3 citations
Hairy cell leukemia variant and WHO classification correspondence Re: 5edition WHO classification haematolymphoid tumors: lymphoid neoplasms.
Michael Grever, Leslie Andritsos, Mirela Anghelina, Evgeny Arons, Versha Banerji
Leukemia. 2024-07-01

Lectures

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

American College of Physicians - ACP
Member
American Society of Hematology - ASH
Member
American Association for Cancer Research - AACR
Member
American Society of Clinical Oncology - ASCO
Member